Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 9/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872887 | 0.84 | ACVR1 (0.44) | PIM1ACVR1FGFR1FGFR2FGFR3 | |
| SCHEMBL5873162 | 0.84 | NTRK1 (0.55) | PIM1ACVR1NTRK1 | |
| SCHEMBL5873090 | 0.84 | PLK4 (0.47) | ACVR1FGFR1FGFR2FGFR3AURKB | |
| SCHEMBL6506307 | 0.83 | LRRK2 (0.53) | FGFR1PLK4FLT3NTRK1 | |
| SCHEMBL5873038 | 0.83 | NTRK1 (0.40) | ACVR1FGFR1FGFR2FGFR3PLK4 | |
| SCHEMBL5872877 | 0.83 | LRRK2 (0.46) | ACVR1NTRK1 | |
| SCHEMBL5872891 | 0.82 | FLT3 (0.46) | PIM1ACVR1FGFR1FGFR2FGFR3 | |
| SCHEMBL5873036 | 0.76 | IDO1 (0.43) | PIM1FGFR1AURKBFLT3 | |
| SCHEMBL5873069 | 0.76 | KDR (0.43) | ACVR1FGFR1FGFR2FGFR3NTRK1 | |
| SCHEMBL5873142 | 0.73 | ACVR1 (0.39) | PIM1ACVR1FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | PIM1 1909/4885ACVR1 4477/4885FGFR1 3930/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | PIM1 1909/4885ACVR1 4477/4885FGFR1 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.